Insmed to Host Third Quarter 2020 Financial Results Conference Call on Thursday, October 29, 2020

Insemed将于2020年10月29号(星期四)主办2020年第三季度财务业绩电话会议

2020-10-21 05:30:58 BioSpace

本文共1064个字,阅读需3分钟

 Insmed Incorporated , a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2020 financial results on Thursday, October 29, 2020. Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, October 29, 2020 to discuss the financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (833) 340-0284 (domestic) or (236) 712-2425 (international) and referencing conference ID number 8292364. The call will also be webcast live on the company's website at www.insmed.com. A replay of the conference call will be accessible approximately two hours after its completion through November 12, 2020 by dialing (800) 585-8367 (domestic) or (416) 621-4642 (international) and referencing conference ID number 8292364. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com. About Insmed Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product, ARIKAYCE® (amikacin liposome inhalation suspension), is the first and only therapy approved in the United States for the treatment of refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a chronic, debilitating condition that can cause severe and permanent lung damage. Insmed is also advancing brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in bronchiectasis and other inflammatory diseases, and treprostinil palmitil inhalation powder, a treprostinil prodrug formulated as a dry powder for inhalation, which may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com. Contact: Investors: Argot Partners Laura Perry or Heather Savelle (212) 600-1902 Insmed@argotpartners.com Media: Mandy Fahey Senior Director, Corporate Communications Insmed (732) 718-3621 Amanda.fahey@insmed.com  multimedia:http://www.prnewswire.com/news-releases/insmed-to-host-third-quarter-2020-financial-results-conference-call-on-thursday-october-29-2020-301155176.html
以改变严重罕见疾病患者生活为使命的全球生物制药公司Insmed Incorporated今天宣布,将于2020年10月29号(星期四)发布2020年第三季度财报。 Insmed管理层将于2020年10月29号(星期四)美国东部时间上午8:30开始为投资者主持电话会议,讨论财务结果并提供业务最新情况。 股东和其他有关各方可通过拨打(833)340-0284(国内)或(236)712-2425(国际)并参照会议ID号8292364参加电话会议。电话会议还将在公司网站www.insmed.com上进行现场直播。 电话会议的重播将在会议结束至2020年11月12日约两小时后通过拨打(800)585-8367(国内)或(416)621-4642(国际)并参照会议ID号8292364可获得。电话会议的网播也将在公司网站www.insmed.com的投资者关系部分存档90天。 关于Insmed Insmed Incorporated是一家全球生物制药公司,致力于改变严重和罕见疾病患者的生活。INSMED的首个商用产品Arikayce®(阿米卡星脂质体吸入混悬剂)是美国批准的第一个也是唯一一个用于治疗难治性鸟分枝杆菌复合体(MAC)肺部疾病的疗法,作为用于有限或没有替代治疗选择的成人患者的组合抗菌药物方案的一部分。MAC肺病是一种慢性的,使人衰弱的疾病,可导致严重的和永久性的肺损伤。Insmed还在推进brensocatib,这是一种新型的二肽基肽酶1口服可逆抑制剂,具有治疗支气管扩张和其他炎症疾病的潜力;以及treprostinil palmitil吸入粉,这是一种作为吸入用干粉配制的treprostinil前药,可能为包括肺动脉高压在内的罕见肺疾病提供一种差异化的产品模式。欲了解更多信息,请访问www.insmed.com。 联系人: 投资者: 隐语伙伴 劳拉·佩里或希瑟·萨维尔 (212)600-1902 insmed@argotpartners.com 介质: 曼迪·法伊 企业传讯高级主任 内嵌的 (732)718-3621 电子邮件:amanda.fahey@insmed.com 多媒体:http://www.prnewswire.com/news-releases/insmed-to-host-third-quarter-2020-financial-results-conference-call-on-thursday-10ber-29-2020-301155176.html

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文